Orsini Specialty Pharmacy, a pioneer in the treatment of rare diseases and gene therapies, has officially announced the addition of Victor Haddock as Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management. These strategic appointments come at a pivotal time for Orsini as it seeks to expand its innovative healthcare solutions and build on its robust growth trajectory.
Victor Haddock brings over 25 years of seasoned financial expertise within the healthcare industry. His recent role as CFO of Triple-S Management in Puerto Rico and prior leadership positions at MagellanRx and Express Scripts highlight his profound ability to drive strategic initiatives and foster team success. Haddock holds a bachelor’s degree in accounting from the University of Puerto Rico and an MBA from Washington University in St. Louis.
“Having assisted healthcare companies of all sizes in their growth and strategic endeavors, Victor brings with him a wealth of experience and a track record of success,” stated Brandon Tom, CEO of Orsini. “Orsini has entered an exciting period of growth, and I’m eager to see Victor’s contributions to our team as we continue to expand our solutions, invest in our teams and strengthen our infrastructure.”
Get Your Organization Happy Place To Work (HPTW) Certified : Why Workplace Happiness Matters Now More Than Ever
HAPPY PLACE TO WORK INSTITUTE (www.happyplacetowork.org)
Lynda Parker, with a similar tenure of over 25 years in the pharmaceutical and biotech industry, has joined Orsini to head Trade Relations and Account Management. Her extensive experience includes impactful roles at Eisai, Ipsen, Syneos, Eversana, and IQVIA. Parker is renowned for her adept commercial planning and client engagement strategies within the complex healthcare market. She holds a bachelor’s degree in business and managerial economics from the University of Lynchburg.
“Lynda has a passion for helping biopharma manufacturers ensure medicines reach the hands of patients who need them,” Tom added. “I am confident that her breadth of experience affords her a nuanced perspective on our clients’ needs across the patient journey and commercialization process.”
The new appointments follow the retirement of Carla Sawa, former CFO, and Dave Frobel, Senior Vice President of Trade Relations. Both Sawa and Frobel will assist during the transitional period to ensure continuity and success for the new leadership.
